Cargando…

Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy

Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR)-modified T cells has revolutionized the field of immune-oncology, showing remarkable efficacy against hematological malignancies. However, its success in solid tumors is limited by factors such as easy recurrence and poor efficacy. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wenshuai, Pan, Xuanxuan, Chen, Lirong, Cui, Haoshu, Mo, Shaocong, Pan, Yida, Shen, Yuru, Shi, Menglin, Wu, Jianlin, Luo, Feifei, Liu, Jie, Li, Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278966/ https://www.ncbi.nlm.nih.gov/pubmed/37342333 http://dx.doi.org/10.3389/fimmu.2023.1186383

Ejemplares similares

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
por: Huang, Jiawen, et al.
Publicado: (2022)

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience
por: Nan, Feifei, et al.
Publicado: (2022)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
por: Miao, Lele, et al.
Publicado: (2021)

Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism?
por: Huan, Tian, et al.
Publicado: (2022)

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
por: Chen, Xiujin, et al.
Publicado: (2022)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Impact of Manufacturing Procedures on CAR T Cell Functionality
por: Watanabe, Norihiro, et al.
Publicado: (2022)

Optimization of T Cell Redirecting Strategies: Obtaining Inspirations From Natural Process of T Cell Activation
por: Gao, Yiyuan, et al.
Publicado: (2021)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
por: Ramírez-Chacón, Alejandro, et al.
Publicado: (2022)

CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
por: To, Van, et al.
Publicado: (2022)

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
por: Xu, Xinjie, et al.
Publicado: (2021)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

Reactions Related to CAR-T Cell Therapy
por: Miao, Lele, et al.
Publicado: (2021)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
por: DeRenzo, Christopher, et al.
Publicado: (2019)

Advances in Universal CAR-T Cell Therapy
por: Lin, Haolong, et al.
Publicado: (2021)

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
por: Zhang, Huanxin, et al.
Publicado: (2022)

Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments
por: Ramírez-Chacón, Alejandro, et al.
Publicado: (2022)

Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
por: York, Jarrod, et al.
Publicado: (2022)

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
por: Martinez, Marina, et al.
Publicado: (2019)

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
por: Andrea, Alain E., et al.
Publicado: (2022)

Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing
por: Zhang, Tingting, et al.
Publicado: (2022)

CAR T Cell Therapy for Neuroblastoma
por: Richards, Rebecca M., et al.
Publicado: (2018)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
por: Watanabe, Keisuke, et al.
Publicado: (2018)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells
por: Qin, Ya-Ting, et al.
Publicado: (2023)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
por: Xu, Xinjie, et al.
Publicado: (2019)

Recent advances in CAR-T cells therapy for colorectal cancer
por: Qin, Xiaoling, et al.
Publicado: (2022)

Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020)

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis
por: Moorman, Cody D., et al.
Publicado: (2023)

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
por: Chen, Kun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rlmn1tsbtoo899qfnr8a7lvuah